BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

22 related articles for article (PubMed ID: 18566996)

  • 1. Retraction Note: Non-thermal plasma inhibits human cervical cancer HeLa cells invasiveness by suppressing the MAPK pathway and decreasing matrix metalloproteinase-9 expression.
    Li W; Yu KN; Bao L; Shen J; Cheng C; Han W
    Sci Rep; 2024 Jun; 14(1):12785. PubMed ID: 38834769
    [No Abstract]   [Full Text] [Related]  

  • 2. Review and Application of Integrin Alpha v Beta 6 in the Diagnosis and Treatment of Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma.
    Lian Y; Zeng S; Wen S; Zhao X; Fang C; Zeng N
    Technol Cancer Res Treat; 2023; 22():15330338231189399. PubMed ID: 37525872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor specific delivery and therapy mediate by integrin β6-target immunoliposomes for β6-siRNA in colon carcinoma.
    Song L; Fan Z; Jun N; Benjia L; Zequn L; Xilong W; Zhongming J; Yong H; Xiaohong W; Kai C; Zhenlin Y
    Oncotarget; 2016 Dec; 7(51):85163-85175. PubMed ID: 27835891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of integrin αvβ6 expression effects on gastric carcinoma invasiveness and progression via cancer-associated fibroblasts.
    Zhuang Z; Zhou R; Xu X; Tian T; Liu Y; Liu Y; Lian P; Wang J; Xu K
    Med Oncol; 2013; 30(3):580. PubMed ID: 23673986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of the β6 gene to suppress degradation of ECM via inactivation of the MAPK pathway in breast adenocarcinoma cells.
    Zhang Y; Wei L; Yu J; Li G; Zhang X; Wang A; He Y; Li H; Yin D
    Oncol Rep; 2014 Nov; 32(5):1787-95. PubMed ID: 25176506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between alphavbeta6 integrin expression, elevated p42/44 kDa MAPK, and plasminogen-dependent matrix degradation in ovarian cancer.
    Ahmed N; Pansino F; Baker M; Rice G; Quinn M
    J Cell Biochem; 2002; 84(4):675-86. PubMed ID: 11835393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sphingosine kinase 1 enhances colon cancer cell proliferation and invasion by upregulating the production of MMP-2/9 and uPA via MAPK pathways.
    Liu SQ; Huang JA; Qin MB; Su YJ; Lai MY; Jiang HX; Tang GD
    Int J Colorectal Dis; 2012 Dec; 27(12):1569-78. PubMed ID: 22684547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells.
    Wu XL; Lin KJ; Bai AP; Wang WX; Meng XK; Su XL; Hou MX; Dong PD; Zhang JJ; Wang ZY; Shi L
    World J Gastroenterol; 2014 Aug; 20(30):10440-8. PubMed ID: 25132760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer.
    Kim TD; Song KS; Li G; Choi H; Park HD; Lim K; Hwang BD; Yoon WH
    BMC Cancer; 2006 Aug; 6():211. PubMed ID: 16916471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of integrin alphaupsilonbeta6 by RNA interference in colon cancer cells inhibits extracellular matrix degradation through the MAPK pathway.
    Wang J; Zhang Z; Xu K; Sun X; Yang G; Niu W; Liu E; Peng C; Lin P; Wang J; Chen R; Agrez M; Niu J
    Int J Cancer; 2008 Sep; 123(6):1311-7. PubMed ID: 18566996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression.
    Das R; Philip S; Mahabeleshwar GH; Bulbule A; Kundu GC
    IUBMB Life; 2005 Jun; 57(6):441-7. PubMed ID: 16012053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymosin beta4 regulates migration of colon cancer cells by a pathway involving interaction with Ku80.
    Cierniewski CS; Papiewska-Pajak I; Malinowski M; Sacewicz-Hofman I; Wiktorska M; Kryczka J; Wysocki T; Niewiarowska J; Bednarek R
    Ann N Y Acad Sci; 2010 Apr; 1194():60-71. PubMed ID: 20536451
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.